Nicolau Carlos, Sala Evis, Kumar Anita, Goldman Debra A, Schoder Heiko, Hricak Hedvig, Vargas Hebert Alberto
1 Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065.
2 Department of Radiology, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain.
AJR Am J Roentgenol. 2017 Apr;208(4):849-853. doi: 10.2214/AJR.16.17133. Epub 2017 Jan 17.
The purpose of this study is to analyze the F-FDG PET/CT features of solid renal masses detected in patients with lymphoma and to evaluate the ability of PET/CT to differentiate renal cell carcinoma (RCC) from renal lymphomatous involvement.
Thirty-six patients with solid renal masses on PET/CT performed for staging or follow-up of lymphoma were evaluated retrospectively. The features recorded for each renal mass included the following standardized uptake values (SUVs) on PET/CT: the maximum SUV (SUV, the mean SUV (SUV), the ratio of the SUV of the tumor to that of the normal kidney cortex, the ratio of the SUV of the tumor to that of the normal kidney cortex, the ratio of the SUV of the tumor to that of the normal liver, and the ratio of the SUVmean of the tumor to that of the normal liver. Renal mass size and margins (well defined vs infiltrative) and the presence of calcifications were evaluated on CT. Renal biopsy results were used as the reference standard. Relationships between imaging parameters and histopathologic findings were assessed.
Of the 36 renal masses evaluated, 22 (61.1%) were RCCs and 14 (38.9%) were renal lymphomas. All SUV metrics were higher for renal lymphomas than for RCCs (p < 0.0001, for all). All renal lymphomas had an SUV higher than 5.98 g/mL (median, 10.99 g/mL), whereas all RCCs had an SUV lower than 5.26 g/mL (median, 2.91 g/mL). No statistically significant differences in mass size or margins were found between RCCs and renal lymphoma.
PET/CT features may be useful for differentiating RCCs from renal involvement in patients with lymphoma with solid renal masses.
本研究旨在分析淋巴瘤患者中检测到的实性肾肿块的F-FDG PET/CT特征,并评估PET/CT区分肾细胞癌(RCC)与肾淋巴瘤累及的能力。
回顾性评估36例因淋巴瘤分期或随访而行PET/CT检查发现实性肾肿块的患者。记录每个肾肿块在PET/CT上的特征,包括以下标准化摄取值(SUV):最大SUV(SUVmax)、平均SUV(SUVmean)、肿瘤SUV与正常肾皮质SUV的比值、肿瘤SUV与正常肝SUV的比值以及肿瘤SUVmean与正常肝SUVmean的比值。在CT上评估肾肿块大小、边缘(边界清晰与浸润性)及钙化情况。肾活检结果作为参考标准。评估影像参数与组织病理学结果之间的关系。
在评估的36个肾肿块中,22个(61.1%)为RCC,14个(38.9%)为肾淋巴瘤。肾淋巴瘤的所有SUV指标均高于RCC(所有p<0.0001)。所有肾淋巴瘤的SUV均高于5.98g/mL(中位数为10.99g/mL),而所有RCC的SUV均低于5.26g/mL(中位数为2.91g/mL)。RCC与肾淋巴瘤在肿块大小或边缘方面未发现统计学显著差异。
PET/CT特征可能有助于区分淋巴瘤合并实性肾肿块患者的RCC与肾受累情况。